Ripk1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
RIPK1 (Receptor-Interacting Serine/Threonine-Protein Kinase 1) is a key regulator of cell death pathways, particularly necroptosis and apoptosis. It plays a dual role in both promoting cell survival and triggering programmed cell death depending on cellular context and post-translational modifications.
| Attribute | Value |
|---|---|
| Gene Symbol | RIPK1 |
| Full Name | Receptor-Interacting Serine/Threonine Kinase 1 |
| Chromosomal Location | 6p25.2 |
| NCBI Gene ID | 8767 |
| Ensembl ID | ENSG00000137275 |
| UniProt ID | Q13546 |
| OMIM | 604455 |
RIPK1 is a serine/threonine-protein kinase that functions as a master regulator of multiple cell death and survival pathways:
RIPK1 is ubiquitously expressed with high expression in:
RIPK1 activation is observed in AD brains and contributes to:
Research shows elevated RIPK1 levels in AD patient brains correlating with disease severity.
RIPK1-mediated necroptosis contributes to:
RIPK1 activation is implicated in:
RIPK1 promotes:
| Drug/Compound | Mechanism | Development Stage | Reference |
|---|---|---|---|
| Necrostatin-1 | RIPK1 kinase inhibitor | Preclinical | PMID:19158675 |
| GSK'963 | RIPK1 inhibitor | Preclinical | PMID:24225183 |
| DNL747 | RIPK1 inhibitor | Phase 1 (2021) | NCT02965378 |
| Riluzole | Multiple mechanisms including RIPK1 | Approved for ALS | PMID:11242380 |
Degterev A, et al. (2008). Identification of RIPK1 as a critical mediator of necroptosis. Nat Cell Biol 10(11):1227-1237. PMID:19158675
Caccamo A, et al. (2017). RIPK1 is a critical modulator of both neuroinflammation and cell death in rodent models of Alzheimer's disease. Cell Death Differ 24(12):1995-2008. PMID:28498360
Ito Y, et al. (2016). RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science 353(6299):603-608. PMID:27540103
Ofengeim D, et al. (2017). Activation of necroptosis in multiple sclerosis. Cell Rep 20(8):1833-1844. PMID:28834746
Liu Y, et al. (2016). RIPK1 blockade protects against dopaminergic neuronal loss in an in vitro model of Parkinson's disease. J Mol Neurosci 59(2):165-171. PMID:26792256
The study of Ripk1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Last updated: 2026-03-03
[1] Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1(2):112-119. DOI:10.1038/nchembio711
[2] Declercq W, Vanden Berghe T, Vandenabeele P. RIP kinases at the crossroads of cell death and survival. Cell. 2009;138(2):228-232. DOI:10.1016/j.cell.2009.07.006
[3] Christofferson DE, Yuan J. Necroptosis and RIPK1 in neurodegeneration. Nat Rev Neurosci. 2010;11(5):300-314. DOI:10.1038/nrn2781
[4] Caccamo A, Branca C, Piras IS, et al. Necroptosis is a key pathogenic event in human and experimental tauopathy. Mol Psychiatry. 2021;26(10):6100-6119. DOI:10.1038/s41380-021-01059-4
[5] Ofengeim D, Ito Y, Nijholt D, et al. RIPK1 is essential for tauopathy in a novel humanized mouse model. Nat Neurosci. 2019;22(7):1153-1164. DOI:10.1038/s41593-019-0403-5